Meloxicam vs Ibuprofen for Anti-inflammatory and Analgesic Therapy

Key Pharmacologic Differences

For simple analgesia without significant inflammation, ibuprofen at low doses (400-1200 mg/day) is preferred due to lower ulcerogenic potential and cost-effectiveness, while meloxicam (7.5-15 mg/day) is superior for chronic inflammatory conditions requiring sustained anti-inflammatory effect with better gastrointestinal safety 1, 2
Ibuprofen is a non-selective COX inhibitor with high analgesic effect at doses with low anti-inflammatory activity, making it less ulcerogenic when used at standard analgesic doses (400-1200 mg/day) 1, 2
The critical distinction: ibuprofen's safety advantage disappears at full anti-inflammatory doses (≥2400 mg/day), where GI bleeding risk becomes comparable to other non-selective NSAIDs 1, 2

At low analgesic doses (<1200 mg/day), ibuprofen has favorable GI safety due to its high analgesic-to-anti-inflammatory ratio 1, 2
This safety advantage is lost at anti-inflammatory doses (≥2400 mg/day), where GI bleeding risk equals other non-selective NSAIDs 1, 2

Effective for acute pain and temporary conditions when used at appropriate analgesic doses 1, 2
For chronic inflammatory conditions requiring sustained anti-inflammatory effect, higher doses are needed, which negates its GI safety advantage 1, 2

Choose ibuprofen when temporary painful conditions (headache, toothache, minor injury) require short-term use at low doses (400-1200 mg/day) 1, 2
Choose ibuprofen when cost is a primary concern and only simple analgesia is needed 3
Choose meloxicam when chronic inflammatory conditions (osteoarthritis, rheumatoid arthritis) require sustained anti-inflammatory effect, and patients are at moderate-to-high GI risk 4

Age ≥60 years, history of peptic ulcer disease, concomitant aspirin/anticoagulant use: these patients require gastroprotection with PPIs regardless of which NSAID is chosen 5
Adding low-dose aspirin to either meloxicam or ibuprofen increases GI complication risk and negates much of meloxicam's safety advantage 4, 7
Cardiovascular disease: both agents require caution, though naproxen has the most favorable CV profile among NSAIDs if anti-inflammatory effect is needed 6, 7

Baseline and every 3 months: blood pressure, BUN, creatinine, liver function studies, CBC, and fecal occult blood 5
Discontinue if: BUN or creatinine doubles, hypertension develops or worsens, or liver function studies increase >3x upper limit of normal 5

Do not use high-dose ibuprofen (≥2400 mg/day) assuming it retains superior GI safety - at these doses, GI bleeding risk equals other NSAIDs 1, 2
Do not prescribe meloxicam for simple acute pain where short-term low-dose ibuprofen would suffice - this is not cost-effective 1, 2
Review NSAID requirements at least every 6 months and consider substituting paracetamol or using "as required" dosing rather than scheduled dosing 3